0001193125-20-268627.txt : 20201113 0001193125-20-268627.hdr.sgml : 20201113 20201013172251 ACCESSION NUMBER: 0001193125-20-268627 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20201013 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aligos Therapeutics, Inc. CENTRAL INDEX KEY: 0001799448 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: ONE CORPORATE DR., 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (800) 466-6059 MAIL ADDRESS: STREET 1: ONE CORPORATE DR., 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 CORRESP 1 filename1.htm CORRESP

J.P. Morgan Securities LLC

383 Madison Avenue

New York, New York 10179

Jefferies LLC

520 Madison Avenue

New York, New York 10022

Piper Sandler & Co.

800 Nicollet Mall, Suite 800

Minneapolis, Minnesota 55402

October 13, 2020

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Healthcare & Insurance

100 F Street, N.E.

Washington, D.C. 20549-6010

 

Attention:

   

Vanessa Robertson

Lynn Dicker

J. Nolan McWilliams

Justin Dobbie

 

Re:

Aligos Therapeutics, Inc.

Registration Statement on Form S-1 (Registration No. 333-249077)

Ladies and Gentlemen:

In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we, as representatives of the several underwriters, hereby join in the request of Aligos Therapeutics, Inc. (the “Company”) for acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-249077) so that it becomes effective as of 4:30 PM, Washington, D.C. time, on October 15, 2020, or as soon as practicable thereafter, or at such other time thereafter as the Company or its outside counsel, Latham & Watkins LLP, may request by telephone to the staff of the U.S. Securities and Exchange Commission.

Pursuant to Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that we have carried out the following distribution of the Company’s preliminary prospectus dated October 9, 2020:

 

  (i)

Dates of distribution: October 9, 2020 through the date hereof

 

  (ii)

Number of prospective underwriters to which the preliminary prospectus was furnished: 4

  (iii)

Number of preliminary prospectuses furnished to investors: approximately 628

 

  (iv)

Number of preliminary prospectuses distributed to others, including the Company, the Company’s counsel, independent accountants and underwriters’ counsel: approximately 26

The undersigned, as representatives of the several underwriters, advise that they have complied and will continue to comply, and each other participating underwriter has advised the undersigned that it has complied and will continue to comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

[Signature Page Follows]

Very truly yours,

J.P. MORGAN SECURITIES LLC

JEFFERIES LLC

PIPER SANDLER & CO.

 

Acting on behalf of themselves and the

several underwriters

 

J.P. MORGAN SECURITIES LLC

By:   /s/ Benjamin Burdett
  Name:   Benjamin Burdett
  Title:   Managing Director
JEFFERIES LLC
By:   /s/ Dustin Tyner
  Name:   Dustin Tyner
  Title:   Managing Director
PIPER SANDLER & CO.
By:   /s/ Chad Huber
  Name:   Chad Huber
  Title:   Managing Director

[Signature Page - Underwriters’ Acceleration Request]